Printer Friendly

Banyu, Maruho Receive NHI Approval for Oral Scabies Medication.

Tokyo, Japan, Aug 25, 2006 - (JCN) - Banyu Pharmaceutical and Maruho Co., Ltd. have announced that an additional indication of Stromectol Tablets 3mg - generic name ivermectin - has been approved for the administration for scabies treatment under the Nippon Health Insurance (NHI) system, alleviating patients' payment for the drug themselves.

Banyu retains approval for the manufacturing and marketing Stromectol in Japan, but has transfered sales rights to Maruho.

Stromectol joins with glutamatergic chloride ion channels, increasing the permeability of the cell membrane to chloride ions which kills parasites. Presently, no effective oral drug has been introduced to treat scabies, so the addition of oral drug Stromectol Tablets 3mg has been encouraged by the health sector in Japan.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Aug 27, 2006
Previous Article:Shimadzu to Release Compact Materials Strength Testing System.
Next Article:Dainippon Launches Cross-advertising Media Service for Mobile.

Related Articles
Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug.
Maruho to Distribute STROMECTOL in Japan.
Meiji Dairies, Kyowa Hakko Kogyo Receive Approval for MRI Digestive Tract Contrast Medium BOTHDEL.
Tanabe Seiyaku, Maruho Conclude Licensing Agreement for Phosphodiesterase 4 Inhibitor, External Agent for Skin Disease.
Ono Pharmaceutical, Banyu Pharmaceutical Jointly Confirm Hypoglycemic Effect of DPP4 Inhibitor Sitagliptin.
Banyu and Ono Begins Phase III Clinical Trials of a DPP-4 Inhibitor for Type 2 Diabetes Patients.
Chugai to Launch HIV Protease Inhibitor INVIRASE(R) Tablet 500mg on September 15.
HCPro expands into managed care field with purchase of National Health Information.
Integrase inhibitor MK-0518: Merck opens expanded-access program.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters